Japan's Takara Bio soars on gene therapy deal with Otsuka
10/04/2018 01:32
** Biotechnologial co Takara Bio 4974.T soars 8.2 pct to
2,300 yen, highest since December 2013
** Co says that it has entered into an agreement with Otsuka
Pharmaceutical Co., Ltd for co-development and exclusive sales
rights in Japan for Takara's NY-ESO-1 siTCRTM (TBI-1301,
TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies
** As of the previous close, the stock had risen 39.77
percent so far this year.
** As of 0013 GMT, about 782,800 shares of the
Shiga-ken-based company have been traded, about 112.9 percent of
their 30-day moving average of 693,470 shares a day.
** Among the 7 analysts that cover Takara Bio Inc, the
current average rating on the shares is "buy"; the breakdown of
recommendations is 6 "strong buy" or "buy", one "hold" and no
"sell" or "strong sell". The analyst mean price target is
2,038.33 yen.
** The forward price-to-earnings ratio for Takara Bio Inc
for the next 12 months is 95.29, about 29.59 percent higher
than it was at the end of last year.
(Reuters
Messaging:ayai.tomisawa.thomsonreuters.com@reuters.net)